6833.HK Stock - Sinco Pharmaceuticals Holdings Limited
Unlock GoAI Insights for 6833.HK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.82B | $2.54B | $2.27B | $2.02B | $2.05B |
| Gross Profit | $299.94M | $323.28M | $305.87M | $364.95M | $273.83M |
| Gross Margin | 10.6% | 12.7% | 13.5% | 18.0% | 13.4% |
| Operating Income | $94.94M | $108.17M | $89.95M | $166.39M | $142.98M |
| Net Income | $42.05M | $42.35M | $69.46M | $135.08M | $118.14M |
| Net Margin | 1.5% | 1.7% | 3.1% | 6.7% | 5.8% |
| EPS | $0.02 | $0.02 | $0.03 | $0.08 | $0.07 |
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
Visit WebsiteEarnings History & Surprises
6833.HKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 28, 2025 | — | $0.01 | — | — |
Q3 2024 | Aug 28, 2024 | — | $0.01 | — | — |
Q1 2024 | Mar 27, 2024 | — | $0.01 | — | — |
Q3 2023 | Aug 30, 2023 | — | $0.01 | — | — |
Q1 2023 | Mar 30, 2023 | — | $0.00 | — | — |
Q3 2022 | Aug 31, 2022 | — | $0.04 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.04 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.05 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.06 | — | — |
Q2 2020 | Jun 30, 2020 | — | $0.02 | — | — |
Q4 2019 | Dec 31, 2019 | — | $0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $0.01 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.16 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.03 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.11 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.02 | — | — |
Q1 2017 | Mar 28, 2017 | — | $-0.01 | — | — |
Q3 2016 | Aug 29, 2016 | — | $0.02 | — | — |
Q2 2016 | Apr 29, 2016 | — | $0.02 | — | — |
Q2 2015 | Jun 30, 2015 | — | $0.05 | — | — |
Latest News
Frequently Asked Questions about 6833.HK
What is 6833.HK's current stock price?
What is the analyst price target for 6833.HK?
What sector is Sinco Pharmaceuticals Holdings Limited in?
What is 6833.HK's market cap?
Does 6833.HK pay dividends?
Similar Stocks
Communication Services SectorExplore stocks similar to 6833.HK for comparison